Stage IVB Prostate Cancer AJCC v8 Completed Phase 2 Trials for Tremelimumab (DB11771)

IndicationStatusPhase
DBCOND0109404 (Stage IVB Prostate Cancer AJCC v8)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03204812Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerTreatment